Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1982 1
1983 1
1985 2
1986 1
1987 2
1988 2
1989 2
1990 1
1991 3
1992 1
1996 2
1998 4
1999 1
2000 3
2001 9
2002 15
2003 5
2004 7
2005 9
2006 9
2007 27
2008 34
2009 42
2010 55
2011 69
2012 90
2013 113
2014 137
2015 157
2016 183
2017 152
2018 177
2019 156
2020 156
2021 36
Text availability
Article attribute
Article type
Publication date

Search Results

1,435 results
Results by year
Filters applied: . Clear all
Page 1
BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Bogeljić Patekar M, Milunović V, Mišura Jakobac K, Perica D, Mandac Rogulj I, Kursar M, Planinc-Peraica A, Ostojić Kolonić S. Bogeljić Patekar M, et al. Acta Clin Croat. 2018 Sep;57(3):542-553. doi: 10.20471/acc.2018.57.03.18. Acta Clin Croat. 2018. PMID: 31168188 Free PMC article. Review.
- The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistan …
- The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for trea …
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.
Grade 3-5 adverse events occurred in 132 (68%) of 194 patients in the obinutuzumab plus bendamustine group and in 123 (62%) of 198 patients in the bendamustine monotherapy group. ...Three (25%) of 12 adverse event-related deaths in the obinutuzumab plus bendamust
Grade 3-5 adverse events occurred in 132 (68%) of 194 patients in the obinutuzumab plus bendamustine group and in 123 (62%) of 198 pa …
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R. LaCasce AS, et al. Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27. Blood. 2018. PMID: 29703778 Free PMC article. Clinical Trial.
Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m(2)) on days 1 and 2 of a 21-day cycle for up to 6 cycles. ...A protocol amendment requiring premedication reduced IRR severity. BV plus bendamustine as first salvage therapy in relapsed/refractory H …
Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m(2)) on days 1 and 2 of a 21-day cycle for up to 6 cycles. ...A pr …
Bendamustine associated immune suppression and infections during therapy of hematological malignancies.
Gafter-Gvili A, Polliack A. Gafter-Gvili A, et al. Leuk Lymphoma. 2016;57(3):512-9. doi: 10.3109/10428194.2015.1110748. Epub 2015 Dec 23. Leuk Lymphoma. 2016. PMID: 26696321 Review.
Bendamustine is being increasingly used in patients with indolent non-Hodgkin lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. ...In addition, hypogammaglobulinemia after bendamustine therapy has also been reported. Variable infection rates have been
Bendamustine is being increasingly used in patients with indolent non-Hodgkin lymphoma, mantle cell lymphoma and chronic lymphocytic
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas. Rummel M, et al. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655425 Clinical Trial.
Thus, 219 patients were included in the per-protocol analysis (114 bendamustine plus rituximab, 105 fludarabine plus rituximab). 1-year progression-free survival with bendamustine plus rituximab was 076 (95% CI 068-084) and 048 (039-058) with fludarabine plus rituxi …
Thus, 219 patients were included in the per-protocol analysis (114 bendamustine plus rituximab, 105 fludarabine plus rituximab). 1-ye …
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL. Cheson BD, et al. Leuk Lymphoma. 2016;57(4):766-82. doi: 10.3109/10428194.2015.1099647. Epub 2015 Nov 23. Leuk Lymphoma. 2016. PMID: 26592922 Free PMC article. Review.
Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2 …
Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lympho …
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Cheson BD, et al. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584548 Clinical Trial.
Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated with obinutuzumab (GA101; G) and bendamustine (B). Patients and Methods Patients with histologically documented, rit …
Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non-Hodgkin …
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. Visco C, et al. Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5. Lancet Haematol. 2017. PMID: 27927586 Clinical Trial.
BACKGROUND: The combination of rituximab, bendamustine, and cytarabine (R-BAC) was highly active in a pilot trial of mantle cell lymphoma, but its use was restricted by high haematological toxicity. ...All patients received RBAC500 (rituximab 375 mg/m(2) on day 1, benda
BACKGROUND: The combination of rituximab, bendamustine, and cytarabine (R-BAC) was highly active in a pilot trial of mantle cell lymp …
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS. Hill BT, et al. Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21. Br J Haematol. 2019. PMID: 30575016 Free PMC article. Clinical Trial.
Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. ...
Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. ...
1,435 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page